Equities

Liquidia Corp

Liquidia Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.65
  • Today's Change0.50 / 4.93%
  • Shares traded1.05m
  • 1 Year change+58.48%
  • Beta0.1910
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

  • Revenue in USD (TTM)15.61m
  • Net income in USD-119.48m
  • Incorporated2020
  • Employees136.00
  • Location
    Liquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
  • Phone+1 (919) 328-4400
  • Fax+1 (919) 328-4402
  • Websitehttps://www.liquidia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ASP Isotopes Inc2.30m-27.05m548.67m76.00--36.50--239.00-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Eyepoint Pharmaceuticals Inc45.71m-103.57m568.60m121.00--2.04--12.44-2.01-2.010.90184.090.19831.05106.19377,793.40-44.94-40.44-59.48-47.7991.4883.45-226.57-186.235.45--0.00--11.14--30.77------
CorMedix Inc12.26m-46.15m626.80m82.00--10.18--51.12-0.8011-0.80110.2121.010.1451----149,539.50-54.61-54.84-64.60-62.3283.576.18-376.35-18,323.423.60--0.00---100.00---56.02--46.27--
Sinovac Biotech Ltd429.20m-130.73m639.90m3.04k------1.49-1.31-1.314.3186.810.03220.20191.08141,325.00-2.2336.14-3.3058.3792.0990.77-69.1965.8711.24--0.0262---69.9714.31-198.16--91.80--
Phathom Pharmaceuticals Inc26.27m-339.45m646.17m452.00------24.60-5.69-5.690.4398-2.740.08422.68--58,119.47-108.79-83.26-126.95-93.7783.54---1,292.14-135,982.005.68-5.601.56-------1.96------
Elite Pharmaceuticals Inc71.17m-6.39m659.87m64.00--13.96--9.27-0.0059-0.00590.06770.04430.89572.684.461,112,051.00-8.0419.07-10.0624.2944.7346.63-8.9820.772.420.750.16340.0065.7949.55464.56--111.50--
Pliant Therapeutics Inc0.00-201.68m781.97m158.00--2.26-----3.34-3.340.005.680.00----0.00-40.90-33.24-43.90-35.39-------360.29----0.0802---83.69---30.83---16.89--
Avid Bioservices Inc142.36m-144.17m783.46m371.00--13.33--5.50-2.27-2.272.240.91920.36613.814.32383,714.30-37.08-0.826-57.59-1.206.2719.26-101.27-2.141.05-3.180.7343---6.2721.15-54,444.79--84.15--
Pacira Biosciences Inc694.96m-90.73m802.49m711.00--1.07--1.15-2.15-2.1513.0316.240.45481.717.03977,436.00-5.943.35-6.833.9874.3572.63-13.068.571.89--0.43930.001.2214.88163.72--0.8761--
Evolus Inc248.33m-55.46m825.71m322.00--140.03--3.33-0.9141-0.91414.110.09311.254.596.61909,619.10-27.90-40.92-38.48-59.7469.9465.43-22.33-80.462.23-2.040.9537--35.98--17.10--182.77--
Liquidia Corp15.61m-119.48m852.59m136.00--7.76--54.62-1.62-1.620.21111.310.0857--4.14114,779.40-65.55-55.02-75.02-62.6964.6582.18-765.37-474.596.33-31.140.5059--9.7545.23-91.40--66.93--
Phibro Animal Health Corp1.05bn17.41m962.37m1.94k55.353.7217.920.91940.42930.429325.826.381.082.606.75539,568.101.803.932.204.9031.4731.181.663.771.692.200.647256.454.074.21-92.59-46.356.650.8548
Collegium Pharmaceutical Inc599.25m88.59m980.73m197.0015.214.184.141.642.002.0013.057.270.42616.252.923,041,853.006.302.799.384.8062.3650.8814.785.160.88323.940.78730.0022.1715.11292.60---54.77--
Avadel Pharmaceuticals PLC (ADR)138.16m-72.58m1.12bn154.00--15.04--8.12-0.7894-0.78941.480.7750.76471.046.38897,142.90-40.17-40.21-54.87-47.9991.92---52.53-374.752.60-6.110.00-----22.99-16.59------
ANI Pharmaceuticals Inc555.46m-8.77m1.17bn642.00--2.9022.762.11-0.4489-0.448928.6720.440.51021.752.96865,196.30-0.6514-2.83-0.7654-3.3559.7960.18-1.28-6.151.970.70180.5921--53.8719.28131.250.17549.08--
Data as of Nov 22 2024. Currency figures normalised to Liquidia Corp's reporting currency: US Dollar USD

Institutional shareholders

37.24%Per cent of shares held by top holders
HolderShares% Held
Caligan Partners LPas of 30 Sep 20248.12m9.75%
BlackRock Fund Advisorsas of 30 Sep 20243.77m4.52%
The Vanguard Group, Inc.as of 30 Sep 20243.29m3.96%
Farallon Capital Management LLCas of 30 Sep 20243.29m3.95%
Findell Capital Management LLCas of 30 Sep 20243.19m3.84%
Kynam Capital Management LPas of 30 Sep 20242.27m2.72%
SSgA Funds Management, Inc.as of 30 Sep 20242.18m2.61%
Whitefort Capital Management, LPas of 30 Sep 20241.70m2.04%
Opaleye Management, Inc.as of 30 Sep 20241.70m2.04%
Vestal Point Capital LPas of 30 Sep 20241.50m1.80%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.